Search Results

You are looking at 101 - 110 of 486 items for :

  • "locally advanced" x
  • Refine by Access: All x
Clear All
Full access

David G. Pfister, Kie-Kian Ang, David M. Brizel, Barbara A. Burtness, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr., Ying J. Hitchcock, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Sandeep Samant, Giuseppe Sanguineti, David E. Schuller, Jatin P. Shah, Sharon Spencer, Andy Trotti III, Randal S. Weber, Gregory T. Wolf, and Frank Worden

% of patients with locally or regionally advanced disease at diagnosis. The treatment of patients with locally advanced T4b or unresectable nodal disease, metastatic disease, or recurrent disease for certain sites, including the oral cavity and pharynx

Full access

Bruce Brockstein, Mario Lacouture, and Mark Agulnik

Edited by Kerrin G. Robinson

receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients . J Clin Oncol 2004 ; 22 : 1646 – 1654 . 40. Soulieres D Senzer NN Vokes EE . Multicenter phase II study of

Full access

Samuel W. Beenken and Marshall M. Urist

, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremity; a multicenter study , Arch Surg 1999 ; 134 : 303 – 307 .

Full access

Andrew H. Ko and Margaret A. Tempero

patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 . J Clin Oncol 2002 ; 20 : 3270 – 3275 . 11 Herrmann R Bodoky G Ruhstaller T . Gemcitabine plus capecitabine versus G alone in locally advanced or

Full access

Prajnan Das, Norio Fukami, and Jaffer A. Ajani

– 867 . 44. Le Chevalier T Smith FP Harter WK . Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma . Semin Oncol 1985 ; 12 : 46 – 53 . 45. Gunderson LL Hoskins RB Cohen AC

Full access

definitive therapy for patients with locally advanced or locoregionally recurrent EGFR -mutant adenocarcinoma of the lung, all patients will receive afatinib induction therapy starting at 40 mg/d (recommended phase II dose in monotherapy studies). Dose

Full access

proteins needed for cell growth and proliferation. Preclinically, MEK inhibitors are exciting candidates for radiosensitization. Trametinib will be used in combination with standard-of-care chemoradiation for locally advanced rectal cancer in this trial

Full access

Harish N. Vasudevan and Sue S. Yom

-dose cisplatin regimen, highlighting a potential benefit to such a treatment approach. In contrast, a prospective randomized phase III study demonstrated that among patients with locally advanced HNC given 100 mg/m 2 cisplatin every 3 weeks versus 30 mg/m 2

Full access

Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh

, NCT01924819). Our large national cohort study of patients with cN+ gastric cancer supports several important conclusions that can help inform the multimodal management of locally advanced gastric cancer as long-term results from clinical trials are

Full access

Ellen L. Jones, Lawrence B. Marks, and Leonard R. Prosnitz

radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group . Lancet 2000 ; 55 : 1119 – 1125 . 24. Kapp DS Cox RS . Thermal treatment